Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jack Schleiffarth

Otolaryngology Rapid City, SD Medical Doctor

NPI 1699972000 CMS profile 411460

4940 5Th St Ste 2B, Rapid City, SD 57701

Open in the dashboard

General payments

$12,990

128 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jack Schleiffarth of Rapid City, SD is reported in the CMS Open Payments database as having received $12,990 across 128 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $247 9
2024 General $3,234 32
2023 General $1,618 55
2022 General $1,216 8
2021 General $623 5
2020 General $61 3
2019 General $5,991 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Schleiffarth
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Jack Schleiffarth were reported at $247. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Jack Schleiffarth Otolaryngology median Middle half National median
2019 $5,991 $194 $82–$512 $163
2020 $61 $118 $42–$280 $114
2021 $623 $167 $63–$444 $132
2022 $1,216 $216 $84–$545 $149
2023 $1,618 $235 $93–$588 $160
2024 $3,234 $280 $111–$699 $164
2025 $247 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inspire Medical Systems, Inc. $6,243 93 payments
  2. Acell, Inc. $5,744 3 payments
  3. Aerin Medical Inc. $353 8 payments
  4. Stryker Corporation $179 3 payments
  5. Advanced Bionics, LLC $127 3 payments
  6. CSL Behring $105 5 payments
  7. Novartis Pharmaceuticals Corporation $63 3 payments
  8. Integra LifeSciences Corporation $35 2 payments
  9. Organogenesis Inc. $26 1 payment
  10. Xoran Technologies $20 1 payment
  11. Other $96 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $5,744 3 payments
  2. Food and Beverage $5,189 120 payments
  3. Travel and Lodging $2,057 5 payments
Products named General payments · program years 2019–2025
  1. INSPIRE $4,656 90 payments
  2. Inspire Upper Airway Stimulation System $1,587 3 payments
  3. RHINAER STYLUS $250 3 payments
  4. VIVAER STYLUS $250 3 payments
  5. MAKO $148 1 payment
  6. HIRES ULTRA CI HIFOCUS MS ELECTRODE $127 3 payments
  7. Haegarda $105 5 payments
  8. Vivaer RF Stylus $84 4 payments
  9. XOLAIR $63 3 payments
  10. INSPIRA AIR $35 2 payments
  11. Other $313 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

479

Median for Otolaryngology: 297

Drug cost

$109,960

Median for Otolaryngology: $6,314

Branded share of claims

28%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 26 $97,033
Arnuity Ellipta Fluticasone Furoate Brand 20 $6,676
Pantoprazole Sodium Generic 118 $1,512
Ipratropium Bromide Generic 60 $1,509
Azelastine Hcl Generic 39 $974
Fluticasone Propionate Generic 37 $500
Ofloxacin Generic 17 $363
Montelukast Sodium Generic 17 $276
Mupirocin Generic 22 $275
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 29 $228

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$118,398

Medicare's payments for the services billed

Medicare patients

482

Average age 73

Services billed

1,343

263 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 50%
Diabetes 22%
Ischemic heart disease 22%
Depression 18%
Osteoporosis 17%
COPD 15%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

128 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record